Soltis Investment Advisors’s Gilead Sciences GILD Stock Holding History

Soltis Investment Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$701K	Buy	5,029 +252	+5%	+$35.3K	0.04%	274
2025 Q4	$586K	Buy	4,777 +467	+11%	+$56.8K	0.04%	301
2025 Q3	$478K	Buy	4,310 +710	+20%	+$80.7K	0.03%	305
2025 Q2	$399K	Sell	3,600 -2,113	-37%	-$225K	0.03%	281
2025 Q1	$640K	Buy	5,713 +3,097	+118%	+$320K	0.06%	208
2024 Q4	$242K	Buy	+2,616	New	+$236K	0.02%	324
2023 Q4	–	Sell	-4,982	Closed	-$373K	–	292
2023 Q3	$373K	Buy	+4,982	New	+$383K	0.05%	198

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Soltis Investment Advisors's GILD Position: Q1 2026 in Review

Soltis Investment Advisors increased its Gilead Sciences (GILD) stake by 5.3% in Q1 2026, buying an estimated $35.3K and bringing the position to 5,029 shares worth $701K. The position accounts for 0.04% of the portfolio, ranked #274.

Soltis Investment Advisors first reported a position in GILD in Q3 2023 and has held it in 7 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Soltis Investment Advisors held 5,029 shares of Gilead Sciences worth $701K as of Q1 2026.
Soltis Investment Advisors bought 252 Gilead Sciences shares in Q1 2026, an estimated $35.3K.
Gilead Sciences made up 0.04% of Soltis Investment Advisors's portfolio in Q1 2026, its #274 holding.
Soltis Investment Advisors first reported a position in Gilead Sciences in Q3 2023 and has held it in 7 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Soltis Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.